Oncology Central

Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma

0

With 65,000 new cases in the USA in 2013, the incidence of kidney cancer has doubled in last decade and accounted for 13,600 deaths in 2013 [1,2]. Renal cell carcinoma (RCC), which consists of 80% of kidney cancers in adults [3], presents with advanced or metastatic stage in approximately a third of patients. A third of early-stage RCC will subsequently recur or progress to metastatic disease after initial nephrectomy [4].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.